• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    2/22/23 4:31:14 PM ET
    $AMWL
    $APRE
    $AQB
    $BIVI
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMWL alert in real time by email

    Gainers

    • TransMedics Group (NASDAQ:TMDX) stock moved upwards by 10.2% to $71.15 during Wednesday's after-market session. The market value of their outstanding shares is at $2.2 billion. As per the news, the Q4 earnings report came out today.
    • AquaBounty Technologies (NASDAQ:AQB) shares rose 6.32% to $0.84. The company's market cap stands at $59.7 million.
    • BioVie (NASDAQ:BIVI) stock increased by 5.83% to $5.99. The market value of their outstanding shares is at $209.5 million.
    • Infinity Pharmaceuticals (NASDAQ:INFI) stock moved upwards by 5.45% to $0.58. The company's market cap stands at $51.8 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares rose 5.02% to $0.23. The market value of their outstanding shares is at $6.8 million.
    • Compass Pathways (NASDAQ:CMPS) stock increased by 4.99% to $9.03. The company's market cap stands at $384.4 million.

    Losers

    • Aprea Therapeutics (NASDAQ:APRE) shares fell 22.4% to $4.9 during Wednesday's after-market session. The market value of their outstanding shares is at $12.9 million.
    • Teladoc Health (NYSE:TDOC) shares declined by 8.23% to $27.01. At the close, Teladoc Health's trading volume reached 682.4K shares. This is 16.1% of its average volume over the last 100 days. The company's market cap stands at $4.3 billion. As per the press release, Q4 earnings came out today.
    • Sorrento Therapeutics (NASDAQ:SRNE) shares decreased by 7.65% to $0.28. This security traded at a volume of 27.3 million shares come close, making up 86.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $155.4 million.
    • Immix Biopharma (NASDAQ:IMMX) stock declined by 6.9% to $2.16. The company's market cap stands at $30.0 million.
    • Tandem Diabetes Care (NASDAQ:TNDM) shares decreased by 6.37% to $37.5. The market value of their outstanding shares is at $2.4 billion. The company's, Q4 earnings came out today.
    • American Well (NYSE:AMWL) shares fell 6.08% to $3.4. The company's market cap stands at $936.3 million. As per the press release, Q4 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMWL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMWL
    $APRE
    $AQB
    $BIVI

    CompanyDatePrice TargetRatingAnalyst
    Immix Biopharma Inc.
    $IMMX
    3/25/2026$20.00Overweight
    Morgan Stanley
    Tandem Diabetes Care Inc.
    $TNDM
    3/19/2026$35.00Hold → Buy
    Truist
    Tandem Diabetes Care Inc.
    $TNDM
    3/17/2026$33.00Neutral → Overweight
    Piper Sandler
    Teladoc Health Inc.
    $TDOC
    3/10/2026$11.00Hold → Buy
    Deutsche Bank
    Immix Biopharma Inc.
    $IMMX
    3/9/2026$23.00Mkt Outperform
    Citizens
    Teladoc Health Inc.
    $TDOC
    2/26/2026$7.00Neutral → Buy
    BofA Securities
    Tandem Diabetes Care Inc.
    $TNDM
    2/23/2026$50.00Hold → Buy
    Lake Street
    Tandem Diabetes Care Inc.
    $TNDM
    2/20/2026$30.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $AMWL
    $APRE
    $AQB
    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Immix Biopharma with a new price target

    Morgan Stanley initiated coverage of Immix Biopharma with a rating of Overweight and set a new price target of $20.00

    3/25/26 8:30:25 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tandem Diabetes Care upgraded by Truist with a new price target

    Truist upgraded Tandem Diabetes Care from Hold to Buy and set a new price target of $35.00

    3/19/26 8:24:11 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Tandem Diabetes Care from Neutral to Overweight and set a new price target of $33.00

    3/17/26 7:55:10 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $AMWL
    $APRE
    $AQB
    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Catapano Joseph Ronald

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    4/3/26 3:58:27 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Gotlib Phyllis

    4 - American Well Corp (0001393584) (Issuer)

    4/2/26 5:20:25 PM ET
    $AMWL
    Real Estate

    SEC Form 4 filed by Zamansky Dmitry

    4 - American Well Corp (0001393584) (Issuer)

    4/2/26 5:13:33 PM ET
    $AMWL
    Real Estate

    $AMWL
    $APRE
    $AQB
    $BIVI
    SEC Filings

    View All

    American Well Corporation filed SEC Form 8-K: Leadership Update

    8-K - American Well Corp (0001393584) (Filer)

    4/2/26 5:06:06 PM ET
    $AMWL
    Real Estate

    Aprea Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

    4/1/26 8:45:47 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: AquaBounty Technologies Inc. filed SEC Form 8-K: Changes in Control of Registrant, Leadership Update

    8-K/A - AQUABOUNTY TECHNOLOGIES INC (0001603978) (Filer)

    3/31/26 8:11:34 AM ET
    $AQB
    Meat/Poultry/Fish
    Consumer Staples

    $AMWL
    $APRE
    $AQB
    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $5,073 worth of shares (5,700 units at $0.89), increasing direct ownership by 21% to 33,433 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:05:34 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Duey Marc bought $25,000 worth of shares (21,459 units at $1.17), increasing direct ownership by 9% to 256,155 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    12/11/25 8:31:55 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMWL
    $APRE
    $AQB
    $BIVI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $AMWL
    $APRE
    $AQB
    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial markets close on Thursday, May 7, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI870b

    4/2/26 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

    DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing. Total gross proceeds from the offering are approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the "Offering"). The Offering closed on March 31, 2026. The Company intends to use the upfront net proceeds for general corporate purposes and for research a

    4/1/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    $AMWL
    $APRE
    $AQB
    $BIVI
    Financials

    Live finance-specific insights

    View All

    Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial markets close on Thursday, May 7, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI870b

    4/2/26 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Teladoc Health Reports Fourth Quarter and Full Year 2025 Results

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 ("Fourth Quarter 2025") and full year ended December 31, 2025 ("Full Year 2025"). Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2024 ("Fourth Quarter 2024") and full year ended December 31, 2024 ("Full Year 2024"). Highlights Fourth Quarter 2025 revenue of $642.3 million, flat year-over-year, and Full Year 2025 revenue of $2,530.0 million, down 2% year-over-yearFourth Quarter 2025 net loss of $25.1 million, or $0.14 per share, and Full Year 2

    2/25/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

    ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights Total revenue of $160.8 million in the fourth quarter of 2025, a 32% increase compared to the fourth quarter of 2024Total revenue of $605.5 million in the full year 2025, a 37% increase compared to the full year 2024Generated net income of $105.4 m

    2/24/26 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMWL
    $APRE
    $AQB
    $BIVI
    Leadership Updates

    Live Leadership Updates

    View All

    Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors

    NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workforce technology solutions and staffing services to healthcare facilities across the US. She joins following the retirements of Eric Evans and Thomas McKinley and the appointment of Michael Smith. She will serve on the board's audit and compensation committees. "Susan brings a powerful combination of healthcare leadership and governance experience to the Board," said Kenneth H. Paulus, non‑

    3/30/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical developmentCapital is in place to support key milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trial DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targe

    3/16/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

    DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea at an important time, following the Company's recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive wit

    2/4/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMWL
    $APRE
    $AQB
    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:35:16 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:20:24 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $AMWL
    $APRE
    $AQB
    $BIVI
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care